Furthermore, we followed up with eight patients to monitor the changes of SALL4 expression during the course of AML treatment at three time points, which included the untreated acute phase, the improving phase (whereby the patient was responding to the chemotherapy as indicated by decreased blast counts, and was at the mid-point of their treatment cycles), and the end of the treatment cycle (of eight patients, five in complete remission (CR) phase, and the other three were in relapse phase). The gene discussed is SALL4; the disease is acute myeloid leukemia.